Levosimendan Improves Calcium Sensitivity of Diaphragm Muscle Fibres from a Rat Model of Heart Failure

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2010 Oct 1

PMID 20880026

Citations 18

Authors

H W H van Hees

Gl Andrade Acuna

M Linkels

P N R Dekhuijzen

L M A Heunks

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Diaphragm muscle weakness occurs in patients with heart failure (HF) and is associated with exercise intolerance and increased mortality. Reduced sensitivity of diaphragm fibres to calcium contributes to diaphragm weakness in HF. Here we have investigated the ability of the calcium sensitizer levosimendan to restore the reduced calcium sensitivity of diaphragm fibres from rats with HF.

Experimental Approach: Coronary artery ligation in rats was used as an animal model for HF. Sham-operated rats served as controls. Fifteen weeks after induction of HF or sham operations animals were killed and muscle fibres were isolated from the diaphragm. Diaphragm fibres were skinned and activated with solutions containing incremental calcium concentrations and 10 µM levosimendan or vehicle (0.02% DMSO). Developed force was measured at each calcium concentration, and force-calcium concentration relationships were plotted.

Key Results: Calcium sensitivity of force generation was reduced in diaphragm muscle fibres from HF rats, compared with fibres from control rats (P < 0.01). Maximal force generation was ∼25% lower in HF diaphragm fibres than in control fibres (P < 0.05). Levosimendan significantly increased calcium sensitivity of force generation in diaphragm fibres from HF and control rats, without affecting maximal force generation.

Conclusions And Implications: Levosimendan enhanced the force generating capacity of diaphragm fibres from HF rats by increasing the sensitivity of force generation to calcium concentration. These results provide strong support for testing the effect of calcium sensitizers on diaphragm muscle weakness in patients with HF.

Citing Articles

Levosimendan's Effects on Length-Dependent Activation in Murine Fast-Twitch Skeletal Muscle.

Haug M, Michael M, Ritter P, Kovbasyuk L, Vazakidou M, Friedrich O Int J Mol Sci. 2024; 25(11).

PMID: 38892380 PMC: 11172453. DOI: 10.3390/ijms25116191.

The carbon monoxide prodrug oCOm-21 increases Ca sensitivity of the cardiac myofilament.

Payne F, Nie S, Diffee G, Wilkins G, Larsen D, Harrison J Physiol Rep. 2024; 12(6):e15974.

PMID: 38491822 PMC: 10943376. DOI: 10.14814/phy2.15974.

Small molecule drugs to improve sarcomere function in those with acquired and inherited myopathies.

Claassen W, Baelde R, Galli R, de Winter J, Ottenheijm C Am J Physiol Cell Physiol. 2023; 325(1):C60-C68.

PMID: 37212548 PMC: 10281779. DOI: 10.1152/ajpcell.00047.2023.

Exercise Capacity Is Improved by Levosimendan in Heart Failure and Sarcopenia via Alleviation of Apoptosis of Skeletal Muscle.

Wang D, Song M, Shen L, Han L, Zhu P, Jia X Front Physiol. 2022; 12:786895.

PMID: 35126176 PMC: 8811365. DOI: 10.3389/fphys.2021.786895.

Troponin Variants in Congenital Myopathies: How They Affect Skeletal Muscle Mechanics.

van de Locht M, Borsboom T, Winter J, Ottenheijm C Int J Mol Sci. 2021; 22(17).

PMID: 34502093 PMC: 8430961. DOI: 10.3390/ijms22179187.

References

Sorsa T, Pollesello P, Permi P, Drakenberg T, Kilpelainen I . Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. J Mol Cell Cardiol. 2003; 35(9):1055-61. DOI: 10.1016/s0022-2828(03)00178-0. View

Kleber F, Vietzke G, Wernecke K, Bauer U, Opitz C, Wensel R . Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation. 2000; 101(24):2803-9. DOI: 10.1161/01.cir.101.24.2803. View

Geiger P, Cody M, Sieck G . Force-calcium relationship depends on myosin heavy chain and troponin isoforms in rat diaphragm muscle fibers. J Appl Physiol (1985). 1999; 87(5):1894-900. DOI: 10.1152/jappl.1999.87.5.1894. View

Carmo M, Barbara C, Ferreira T, Branco J, Ferreira S, Rendas A . Diaphragmatic function in patients with chronic left ventricular failure. Pathophysiology. 2001; 8(1):55-60. DOI: 10.1016/s0928-4680(01)00065-7. View

Meyer F, Borst M, Zugck C, Kirschke A, Schellberg D, Kubler W . Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation. 2001; 103(17):2153-8. DOI: 10.1161/01.cir.103.17.2153. View

Ukkonen H, Saraste M, Akkila J, Knuuti M, Lehikoinen P, Nagren K . Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther. 1997; 61(5):596-607. DOI: 10.1016/S0009-9236(97)90139-9. View

Meyer F, Zugck C, Haass M, Otterspoor L, Strasser R, Kubler W . Inefficient ventilation and reduced respiratory muscle capacity in congestive heart failure. Basic Res Cardiol. 2000; 95(4):333-42. DOI: 10.1007/s003950070053. View

Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I . The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol. 2004; 486(1):67-74. DOI: 10.1016/j.ejphar.2003.12.005. View

Michaels A, McKeown B, Kostal M, Vakharia K, Jordan M, Gerber I . Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. 2005; 111(12):1504-9. DOI: 10.1161/01.CIR.0000159252.82444.22. View

10.

Lunde P, Sejersted O, Thorud H, Tonnessen T, Henriksen U, Christensen G . Effects of congestive heart failure on Ca2+ handling in skeletal muscle during fatigue. Circ Res. 2006; 98(12):1514-9. DOI: 10.1161/01.RES.0000226529.66545.e5. View

11.

McParland C, Krishnan B, Wang Y, Gallagher C . Inspiratory muscle weakness and dyspnea in chronic heart failure. Am Rev Respir Dis. 1992; 146(2):467-72. DOI: 10.1164/ajrccm/146.2.467. View

12.

Antila S, Sundberg S, Lehtonen L . Clinical pharmacology of levosimendan. Clin Pharmacokinet. 2007; 46(7):535-52. DOI: 10.2165/00003088-200746070-00001. View

13.

Kaheinen P, Pollesello P, Levijoki J, Haikala H . Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol. 2004; 43(4):555-61. DOI: 10.1097/00005344-200404000-00011. View

14.

Burkholder T, Lieber R . Sarcomere length operating range of vertebrate muscles during movement. J Exp Biol. 2001; 204(Pt 9):1529-36. DOI: 10.1242/jeb.204.9.1529. View

15.

Kurotobi T, Sato H, Yokoyama H, Li D, Koretsune Y, Ohnishi Y . Respiratory oxygen cost for dead space challenge is characteristically increased during exercise in patients with chronic heart failure: does it further decrease exercise capacity?. J Card Fail. 1997; 3(3):181-8. DOI: 10.1016/s1071-9164(97)90014-2. View

16.

Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H . Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000; 68(5):522-31. DOI: 10.1067/mcp.2000.110972. View

17.

Mancini D, Henson D, LaManca J, Levine S . Respiratory muscle function and dyspnea in patients with chronic congestive heart failure. Circulation. 1992; 86(3):909-18. DOI: 10.1161/01.cir.86.3.909. View

18.

Nieminen M, Akkila J, Hasenfuss G, Kleber F, Lehtonen L, Mitrovic V . Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36(6):1903-12. DOI: 10.1016/s0735-1097(00)00961-x. View

19.

Edes I, Kiss E, Kitada Y, Powers F, Papp J, Kranias E . Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res. 1995; 77(1):107-13. DOI: 10.1161/01.res.77.1.107. View

20.

Faggiano P, DAloia A, Gualeni A, Giordano A . Relative contribution of resting haemodynamic profile and lung function to exercise tolerance in male patients with chronic heart failure. Heart. 2001; 85(2):179-84. PMC: 1729632. DOI: 10.1136/heart.85.2.179. View